Repligen director awarded RSUs and options

Repligen Corporation director Nicolas Barthelemy reported compensation-related equity grants.

Rhea-AI Filing Summary

Repligen Corporation director Nicolas Barthelemy reported compensation-related equity grants. He was awarded 995 restricted stock units, each representing one share of Common Stock, and 2,239 stock options with an exercise price of $103.38 per share.

The RSUs and option award vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual shareholder meeting. Barthelemy has elected to defer settlement of the RSUs under Repligen’s Deferred Compensation Plan for Non-Employee Directors, with shares to be delivered after his service as a director ends. Following these grants, he directly holds 5,436 shares of Common Stock and 2,239 options.

Insider Trade Summary

Grant/Award: 3,234 shares

Grant/Award 2 txns

Insider BARTHELEMY NICOLAS

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,239	$0.00	$0.00
Grant/Award	Common Stock	995	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 2,239 contracts (Direct); Common Stock — 5,436 shares (Direct)

Footnotes (2)

1. F1. Mr. Barthelemy was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
2. F2. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Key Figures

RSU grant: 995 units Option grant size: 2,239 options Option exercise price: $103.38 per share +4 more

7 metrics

RSU grant 995 units Restricted stock units awarded to director on May 14, 2026

Option grant size 2,239 options Stock Option (Right to Buy) awarded on May 14, 2026

Option exercise price $103.38 per share Conversion/exercise price for 2,239 stock options

Common shares held after grant 5,436 shares Total Common Stock directly owned following RSU grant

Options held after grant 2,239 options Total Stock Option (Right to Buy) position following grant

Option vesting date trigger May 14, 2027 Options vest on earlier of this date or next annual meeting

Option expiration May 14, 2036 Expiration date of Stock Option (Right to Buy)

Key Terms

restricted stock units, Deferred Compensation Plan for Non-Employee Directors, Stock Option (Right to Buy), Grant, award, or other acquisition, +1 more

5 terms

restricted stock units financial

"Mr. Barthelemy was awarded 995 restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Deferred Compensation Plan for Non-Employee Directors financial

"defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors."

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vest in full financial

"Award vests in full on the earlier of May 14, 2027..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Repligen (RGEN) director Nicolas Barthelemy receive in this Form 4 filing?

Nicolas Barthelemy received equity compensation awards. He was granted 995 restricted stock units and 2,239 stock options for Repligen Common Stock, reflecting routine director compensation rather than an open-market stock purchase or sale.

How large are Nicolas Barthelemy’s new stock option awards in Repligen (RGEN)?

Barthelemy received 2,239 stock options. These options give him the right to buy 2,239 Repligen Common Stock shares at an exercise price of $103.38 per share, vesting on the earlier of May 14, 2027 or the next annual shareholder meeting.

When do Nicolas Barthelemy’s restricted stock units in Repligen (RGEN) vest?

The 995 restricted stock units vest in a single tranche. They vest on the earlier of May 14, 2027, one year from the grant date, or the date of Repligen’s next annual shareholders’ meeting, which the company notes has not yet been determined.

How are Nicolas Barthelemy’s RSUs in Repligen (RGEN) settled after vesting?

The RSUs are settled in Repligen Common Stock after service ends. Barthelemy elected to defer settlement under the Deferred Compensation Plan for Non-Employee Directors, so vested shares will be issued following his separation from service as a director.

What does the Form 4 show about Nicolas Barthelemy’s Repligen (RGEN) holdings after these grants?

After the grants, Barthelemy holds additional equity exposure. He directly owns 5,436 shares of Repligen Common Stock and 2,239 stock options linked to Common Stock, all reported as direct ownership in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BARTHELEMY NICOLAS

(Last) (First) (Middle)

C/O REPLIGEN CORPORATION

41 SEYON ST., BLDG 1, STE 100

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A		995(1)	A	$0.00	5,436	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$103.38	05/14/2026		A		2,239		05/14/2027(2)	05/14/2036	Common Stock	2,239	$0.00	2,239	D

Explanation of Responses:

1. Mr. Barthelemy was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

	/s/ Jennifer Carmichael (Attorney in Fact)	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)